Year: 2024
Type: dissertation
Abstract: Alzheimer's disease (AD) is the leading cause of dementia globally, affecting 55 million people. This neurodegenerative disorder is characterized by the accumulation of amyloid-beta (AB) in senile plaques and intraneuronal tau-protein tangles, leading to neuronal death. In sporadic AD, several factors such as aging, the E4 allele of Apolipoprotein E, female gender and type 2 diabetes can contribute to disrupt brain processes. The disease initiates with the abnormal cleavage of amyloid precursor protein, resulting in AB plaque formation. This accumulation is worsened by inadequate degradation of AB due to chronic inflammation that impairs microglial function, consequently leading to tau hyperphosphorylation, disrupted axonal transport, and neuron death. For over 25 years, the amyloid cascade hypothesis, which identifies AB as the primary trigger of AD, has been the predominant theory. However, alternative hypotheses have emerged, including the cholinergic theory, the mitochondrial cascade hypothesis and theories linking AD to infections and alterations in the gut microbiome. Current treatments for AD focus on managing symptoms, along with newer immunotherapies aimed at blocking disease progression. Future therapeutic approaches are exploring additional immunotherapies, gene-targeted strategies, the use of prebiotics, and kinase inhibitors. Recent research also emphasizes the role of circadian rhythms in AD, with melatonin showing potential not only for addressing sleep disturbances but also as a preventive treatment.
Source: UCrea (University of Cantabria)
Author: Artíguez Calvo, Alba
Institution: Universidad de Cantabria
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W7128137084
